• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Scilex Holding Company filed SEC Form 8-K: Regulation FD Disclosure

    12/1/25 6:15:54 AM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $SCLX alert in real time by email
    8-K
    Scilex Holding Co false 0001820190 0001820190 2025-11-25 2025-11-25 0001820190 sclxw:CommonStockParValue0.0001PerShareMember 2025-11-25 2025-11-25 0001820190 sclxw:WarrantsToPurchaseCommonStockAtAnExercisePriceOf402.50PerShareMember 2025-11-25 2025-11-25
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(d)

    OF THE SECURITIES EXCHANGE ACT OF 1934

    Date of Report (Date of earliest event reported): November 25, 2025

     

     

    SCILEX HOLDING COMPANY

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-39852   92-1062542
    (State or other jurisdiction
    of incorporation)
     

    (Commission

    File Number)

      (IRS Employer
    Identification No.)

    960 San Antonio Road, Palo Alto, California, 94303

    (Address of principal executive offices, including zip code)

    Registrant’s telephone number, including area code: (650) 516-4310

    N/A

    (Former name or former address, if changed since last report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act

     

    Title of each class

     

    Trading
    Symbol(s)

     

    Name of each exchange
    on which registered

    Common stock, par value $0.0001 per share   SCLX   The Nasdaq Stock Market LLC
    Warrants to purchase common stock at an exercise price of $402.50 per share   SCLXW   The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☒

     

     
     


    Item 2.01

    Completion of Acquisition or Disposition of Assets

    Datavault Acquisition

    As previously disclosed, on September 25, 2025, Scilex Holding Company (the “Company”) entered into a Securities Purchase Agreement (the “Datavault SPA”) with Datavault AI Inc., a Delaware corporation (“Datavault”), pursuant to which Datavault agreed to issue and sell, and the Company agreed to purchase, 15.0 million shares (the “Datavault Shares”) of common stock of Datavault (“Datavault Common Stock”) in the initial closing which occurred on September 26, 2025 (the “Initial Closing”) and a pre-funded warrant (the “Pre-Funded Warrant”) to purchase 263,914,094 shares of Datavault Common Stock in a subsequent closing (the “Subsequent Closing”), for an aggregate purchase price of $150 million in Bitcoin (“BTC”) (based on the spot exchange rate for BTC as published by Coinbase.com at 8:00 p.m. (New York City time) on the trading day immediately prior to the date of the Initial Closing Date, or September 25, 2025 (such rate, the “Spot Exchange Rate”)).

    Pursuant to the Datavault SPA, the Subsequent Closing was subject to the satisfaction of the condition that the stockholders of Datavault approve the issuance of the shares of Datavault Common Stock underlying the Pre-Funded Warrant. On November 24, 2025, Datavault obtained such stockholder approval at its annual meeting.

    On November 25, 2025, the Subsequent Closing was consummated with the Company transferring an amount of BTC (based on the Spot Exchange Rate) in satisfaction of the payment of the remainder of the aggregate purchase price to Datavault and Datavault issuing the Pre-Funded Warrant to the Company.

    On November 25, 2025, following the Subsequent Closing, the Company exercised the Pre-Funded Warrant in full for an aggregate exercise price of approximately $26.4 thousand, paid in cash.

    Following the Initial Closing, the Company and Datavault entered into a license agreement providing for the use by the Company of certain intellectual property owned by Datavault. Other than the preceding sentence and the transactions consummated pursuant to the Datavault SPA, there are no material relationships between the Company and Datavault.

    The foregoing summary of the Datavault SPA does not purport to be complete and is qualified in its entirety by reference to the full text of the Datavault SPA, a copy of which is filed herewith as Exhibit 10.1 and is incorporated herein by reference.

     

    Item 7.01.

    Regulation FD Disclosure.

    On November 26, 2025, the Company issued a press release announcing the Subsequent Closing under the Datavault SPA. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

    The information in Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference into any filing by the Company, under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

     


    Item 9.01.

    Financial Statements and Exhibits.

    (d) Exhibits.

     

    Exhibit
    Number

      

    Description

    10.1#    Securities Purchase Agreement, dated September 25, 2025, by and between Scilex Holding Company and Datavault AI Inc. (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed on September 26, 2025).
    99.1    Press release dated November 26, 2025.
    104    Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).

     

    #

    Certain of the exhibits and schedules to this Exhibit have been omitted in accordance with Regulation S-K Item 601. The Company agrees to furnish a copy of all omitted exhibits and schedules to the SEC upon its request.

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    SCILEX HOLDING COMPANY
    By:  

    /s/ Henry Ji, Ph.D.

    Name: Henry Ji, Ph.D.
    Title: Chief Executive Officer & President

    Date: December 1, 2025

    Get the next $SCLX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SCLX

    DatePrice TargetRatingAnalyst
    1/27/2025$22.00Buy
    D. Boral Capital
    10/16/2024$14.00Buy
    Alliance Global Partners
    6/13/2024$13.00Buy
    Rodman & Renshaw
    10/16/2023$4.00Buy
    B. Riley Securities
    10/13/2023$4.00Buy
    B. Riley Securities
    10/9/2023$12.00Buy
    H.C. Wainwright
    More analyst ratings

    $SCLX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Scilex Holding Company Announces Closing of Previously Announced Second Tranche Investment in Datavault AI Inc., Completing Its Two-Tranche Equity Financing in Datavault AI Inc.

    Scilex closed the second tranche, purchasing a pre-funded warrant exercisable for 263,914,094 shares of Datavault AI Inc. (NASDAQ:DVLT, "Datavault AI")) common stock in Bitcoin (BTC) (based on the spot exchange rate of BTC as of the signing of the strategic investment).The closing followed the approval by the Datavault AI stockholders, obtained at Datavault AI's November 24, 2025 annual meeting, of the issuance of the shares of Datavault common stock upon exercise of the pre-funded warrant.Scilex has exercised the warrant in full and the shares of Datavault AI common stock issued upon such exercise have an approximate value of $583.3 million based on the closing price of $2.21 per share of D

    11/26/25 6:00:00 AM ET
    $DVLT
    $SCLX
    Semiconductors
    Technology
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Datavault AI Announces Closing of the Second Tranche of Scilex Holding Company's Previously Announced Equity Financing

    Second tranche closing of approximately 1,237.6 Bitcoin follows approval by Datavault AI's stockholders at annual meeting.Scilex Holding Company purchased a pre-funded warrant exercisable for approximately 263.91 million shares of Datavault AI common stock in connection with the closing of this second tranche.Both companies ramping up collaboration to deliver growth in 2026. PHILADELPHIA, Nov. 26, 2025 (GLOBE NEWSWIRE) -- via IBN -- Datavault® AI (NASDAQ:DVLT, "Datavault" or the "Company")), a provider of data monetization, credentialing, and real-world asset tokenization technologies, today announces that it has closed the second tranche of its previously announced equity financing wi

    11/26/25 6:00:00 AM ET
    $DVLT
    $SCLX
    Semiconductors
    Technology
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scilex Holding Company Announces Closing of Exercise of Warrants for $20.3 Million Gross Proceeds

    PALO ALTO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex" or the "Company") (NASDAQ:SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, announced today the closing of its previously announced exercise of certain existing warrants to purchase an aggregate of (i) 428,572 shares of common stock (the "Common Stock") having an exercise of $38.50 per share and issued in April 2024 (the "April 2024 Warrants") and (ii) 475,824 shares of Common Stock having an exercise price of $22.72 per share

    11/25/25 2:37:04 PM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SCLX
    SEC Filings

    View All

    SEC Form SCHEDULE 13D filed by Scilex Holding Company

    SCHEDULE 13D - Scilex Holding Co (0001820190) (Filed by)

    12/1/25 6:30:43 AM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 424B3 filed by Scilex Holding Company

    424B3 - Scilex Holding Co (0001820190) (Filer)

    12/1/25 6:23:38 AM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 424B3 filed by Scilex Holding Company

    424B3 - Scilex Holding Co (0001820190) (Filer)

    12/1/25 6:21:57 AM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SCLX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Scilex Holding Co exercised 263,914,094 in-the-money shares at a strike of $0.00 and sold $871,161 worth of shares (422,299 units at $2.06), increasing direct ownership by 16,358% to 265,102,560 units (SEC Form 4)

    4 - Scilex Holding Co (0001820190) (Reporting)

    11/28/25 9:44:09 PM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    New insider Scilex Holding Co claimed ownership of 1,610,765 shares (SEC Form 3)

    3 - Scilex Holding Co (0001820190) (Reporting)

    11/28/25 9:41:56 PM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Wu Yue Alexander

    4 - Scilex Holding Co (0001820190) (Issuer)

    10/9/25 8:47:29 AM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SCLX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Scilex Holding Company (Amendment)

    SC 13D/A - Scilex Holding Co (0001820190) (Subject)

    4/25/24 5:25:28 PM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D/A filed by Scilex Holding Company (Amendment)

    SC 13D/A - Scilex Holding Co (0001820190) (Subject)

    3/5/24 4:22:28 PM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SCLX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    D. Boral Capital initiated coverage on Scilex Holding with a new price target

    D. Boral Capital initiated coverage of Scilex Holding with a rating of Buy and set a new price target of $22.00

    1/27/25 8:08:33 AM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Alliance Global Partners initiated coverage on Scilex Holding with a new price target

    Alliance Global Partners initiated coverage of Scilex Holding with a rating of Buy and set a new price target of $14.00

    10/16/24 8:01:57 AM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Rodman & Renshaw initiated coverage on Scilex Holding with a new price target

    Rodman & Renshaw initiated coverage of Scilex Holding with a rating of Buy and set a new price target of $13.00

    6/13/24 7:16:15 AM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SCLX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Shah Jaisim bought $13,800 worth of shares (30,000 units at $0.46), increasing direct ownership by 27% to 139,333 units (SEC Form 4)

    4 - Scilex Holding Co (0001820190) (Issuer)

    12/18/24 7:04:41 PM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Executive Chairperson Ji Henry bought $8,351 worth of shares (8,888 units at $0.94), increasing direct ownership by 3% to 320,161 units (SEC Form 4)

    4 - Scilex Holding Co (0001820190) (Issuer)

    10/31/24 12:44:57 PM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Officer Shah Jaisim bought $31,670 worth of shares (32,000 units at $0.99), increasing direct ownership by 41% to 109,333 units (SEC Form 4)

    4 - Scilex Holding Co (0001820190) (Issuer)

    10/29/24 6:59:31 PM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SCLX
    Financials

    Live finance-specific insights

    View All

    Scilex Holding Company Announces Update Regarding Distribution of Dream Bowl 2026 Meme Coin by Datavault AI Inc.

    PALO ALTO, Calif., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex" or the "Company") (NASDAQ:SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, announced today that, with respect to the voluntary distribution by Datavault AI Inc. ("Datavault AI") (NASDAQ:DVLT) of Dream Bowl 2026 Meme Coins to record holders of Scilex common stock, given that such distribution is being made by Datavault AI as a token of its appreciation for Scilex's relationship with Datavault AI as a stockholder of Datavault A

    11/21/25 3:59:33 PM ET
    $DVLT
    $SCLX
    Semiconductors
    Technology
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Datavault AI Announces Update Regarding Distribution of Dream Bowl 2026 Meme Coin

    PHILADELPHIA, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Datavault AI Inc. ("Datavault AI" or the "Company") (NASDAQ:DVLT), a provider of data monetization, credentialing, digital engagement, and real‑world asset tokenization technologies, announced today that, in connection with its previously announced distribution of Dream Bowl 2026 Meme Coins to eligible record equity holders of Datavault AI, Nasdaq has informed the Company that it is not expecting to quote an ex-dividend date for such distribution and therefore eligible record equity holders of Datavault AI must be holders as of the record date of November 25, 2025 in order to receive the distribution.  With respect to Datavault AI's volunta

    11/21/25 3:56:48 PM ET
    $DVLT
    $SCLX
    Semiconductors
    Technology
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scilex Holding Company Announces that the Board of Directors of Datavault AI Inc. Has Approved the Distribution of a Dream Bowl 2026 Meme Coin to All Eligible Scilex and Datavault AI Stockholders of Record and Set a Record Date of November 25, 2025

    PALO ALTO, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex" or the "Company") (NASDAQ:SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that the Board of Directors of Datavault AI Inc. ("Datavault AI") (NASDAQ:DVLT) has approved the distribution of a Dream Bowl 2026 Meme Coin to all [eligible] Scilex and Datavault AI stockholders of record and set a record date of November 25, 2025 for determining stockholders entitled to receive the Dream Bowl 2026 Meme Coin from Datav

    11/11/25 9:30:00 AM ET
    $DVLT
    $SCLX
    Semiconductors
    Technology
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SCLX
    Leadership Updates

    Live Leadership Updates

    View All

    Scilex Holding Company Strengthens Board of Directors with Appointment of Highly Accomplished Leader in Interventional and Multidisciplinary Spine, Musculoskeletal and Orthopedic Care, Annu Navani, M.D.

    PALO ALTO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or the "Company"))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that it has added to its Board of Directors a highly accomplished leader in interventional and multidisciplinary spine, musculoskeletal and orthopedic care, Annu Navani, M.D. Dr. Navani has served as the Chief Executive Officer of Comprehensive Spine and Sports Center since 2008, a leader in interventional and multidisciplinary spine, musculoskeletal, and orthopedic care. Over th

    7/23/24 9:00:00 AM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scilex Holding Company Launches New Website to Showcase Growing Portfolio of Non-Opioid Products and Pipeline Information Updates

    PALO ALTO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company"))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced the launch of its redesigned website showcasing the Company's growing portfolio of non-opioid pain management therapeutics. The new website can be accessed by visiting www.scilexholding.com, The features of the new and improved website include: Sleek, modern web design with dynamic elements and illustrations;An overview of the Company's science and expanded product portfolio and pr

    3/4/24 9:00:00 AM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care